Statin Use Is Associated With Improved Survival But Not Progression‐Free Outcomes in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab–Bevacizumab
Hepatology Research · 2026-11 · 56 (11) · 1596-1605
DOI: 10.1111/hepr.70232 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatology Research, online erschienen am 06.07.2026. Verfasst von Toshinori Toyota und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Chuo-ku, Kumamoto, Japan. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Aim
Statins contribute to the preservation of hepatic function and reduce the risk of hepatocellular carcinoma (HCC) in patients with chronic liver disease; however, their clinical significance during systemic therapy for unresectable HCC remains unclear. Therefore, we investigated whether baseline statin use influences clinical outcomes in patients with unresectable HCC treated with atezolizumab plus bevacizumab.
Methods
We conducted a multicenter, retrospective cohort study of patients with unresectable HCC treated with atezolizumab–bevacizumab. Patients were classified as statin users or non‐users at treatment initiation. The primary outcome was overall survival (OS), and secondary outcomes included progression‐free survival (PFS) and post‐progression survival (PPS). To adjust for baseline imbalances, inverse probability of treatment weighting (IPTW) was applied, and propensity score (PS) matching was performed as a sensitivity analysis.
Results
A total of 284 patients were included, of whom 50 received statins. In the unadjusted cohort, OS was significantly longer in statin users than in non‐users ( p = 0.026). After IPTW adjustment, this OS benefit remained significant ( p = 0.031). In contrast, PFS did not differ significantly between groups in either the unadjusted ( p = 0.291) or IPTW‐adjusted cohorts ( p = 0.117). PPS was significantly prolonged in the statin group ( p = 0.006), with consistent findings after IPTW adjustment ( p = 0.018). In addition, deterioration in ALBI score was attenuated in statin users, suggesting better preservation of hepatic functional reserve.
Conclusions
Statin use was associated with significantly improved OS and PPS without affecting PFS, likely reflecting host‐related benefits through preservation of hepatic function.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Chuo-ku, Kumamoto, Japan.
- Department of Gastroenterological Surgery, Kumamoto University, Chuo-ku, Kumamoto, Japan.
- Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
- Department of Gastroenterology and Hepatology, Kumamoto Shinto General Hospital, Chuo-ku, Kumamoto, Japan.
- Department of Gastroenterology, Amakusa Medical Center, Amakusa, Japan.
ORCID-Profile: Satoshi Narahara, Yuki Kitano, Hiroki Inada, Munenori Honda, Takehisa Watanabe, Hiroko Setoyama, Hisashi Hidaka, Yasuhito Tanaka
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Toyota, T., Narahara, S., Uojima, H., Kitano, Y., Mizuta, T., Maeda, D., Kurano, S., Tanaka, K., Inada, H., Honda, M., Yoshimaru, Y., Watanabe, T., Nagaoka, K., Setoyama, H., Hayashi, H., Suzuki, T., Matsuura, K., Iwasaki, S., Nomura, N., …, & Tanaka, Y. (2026). Statin Use Is Associated With Improved Survival But Not Progression‐Free Outcomes in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab–Bevacizumab. Hepatology Research, 56(11), 1596-1605. https://doi.org/10.1111/hepr.70232
Vancouver
Toyota T, Narahara S, Uojima H, Kitano Y, Mizuta T, Maeda D, et al. Statin Use Is Associated With Improved Survival But Not Progression‐Free Outcomes in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab–Bevacizumab. Hepatology Research. 2026;56(11):1596-1605. doi:10.1111/hepr.70232
BibTeX
@article{Toyota2026,
author = {Toyota, Toshinori and Narahara, Satoshi and Uojima, Haruki and Kitano, Yuki and Mizuta, Takahiro and Maeda, Daiki and Kurano, Soutarou and Tanaka, Kentaro and Inada, Hiroki and Honda, Munenori and Yoshimaru, Yoko and Watanabe, Takehisa and Nagaoka, Katsuya and Setoyama, Hiroko and Hayashi, Hiromitsu and Suzuki, Takanori and Matsuura, Kentaro and Iwasaki, Shuichiro and Nomura, Nao and Miyase, Shiho and Yuruki, Hideto and Sakai, Yoshinari and Kudo, Koichi and Hidaka, Hisashi and Iwatsuki, Masaaki and Tanaka, Yasuhito},
title = {Statin Use Is Associated With Improved Survival But Not Progression‐Free Outcomes in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab–Bevacizumab},
journal = {Hepatology Research},
year = {2026},
volume = {56},
number = {11},
pages = {1596--1605},
doi = {10.1111/hepr.70232}
}
EUVIMED